CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

December 9, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Stroke
Interventions
DRUG

Low dose tenecteplase

Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)

DRUG

High dose tenecteplase

Intravenous (IV) tenecteplase 0.32 mg/kg (single bolus; maximum dose 32 mg)

Trial Locations (1)

200040

Huashan Hospital, Shanghai

All Listed Sponsors
collaborator

The First Affiliated Hospital of Shanxi Medical University

OTHER

collaborator

Ningbo No. 1 Hospital

OTHER

collaborator

Zhejiang Province People's Hospital

UNKNOWN

collaborator

Shanghai 5th People's Hospital

OTHER

collaborator

Shanghai 10th People's Hospital

OTHER

collaborator

Shanghai 6th People's Hospital

OTHER

collaborator

The Second Affiliated Hospital of Chongqing Medical University

OTHER

collaborator

The Second People's Hospital of Huai'an

OTHER

collaborator

Pu'er City People's Hospital

UNKNOWN

collaborator

ShuGuang Hospital

OTHER

collaborator

Shanghai East Hospital

OTHER

collaborator

First People's Hospital of Shenyang

OTHER

lead

Huashan Hospital

OTHER

NCT04086147 - CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase | Biotech Hunter | Biotech Hunter